ESMO issues updated guidelines on the management of melanoma


  • Dawn O'Shea
  • Univadis Medical News
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

The European Society for Medical Oncology (ESMO) has issued updated guidance on the management of cutaneous melamona. Key recommendations include the following:

Diagnosis

Mandatory mutation testing for actionable mutations for resectable or unresectable stage III or IV and high-risk resected stage IIC (not stage I or IIA-IIB).

Excision safety margin

  • 0.5 cm for in situ melanomas
  • 1 cm for tumours
  • 2 cm for ≥2 mm

Treatment of locoregional disease

  • Complete lymph node dissection (CLND) not recommended for sentinel lymph node (SN)-positive patients.
  • CLND indicated for isolated locoregional clinically-detectable lymph node (LN) metastases.
  • Adjuvant radiotherapy for local tumours with inadequate margins of lentigo maligna melanoma (LMM), for microscopic tumour at the margin (R1), or after resection of bulky disease.
  • Anti-programmed cell death 1 antibodies (PD1) adjuvant therapy or dabrafenib/trametinib are preferred.

Treatment of advanced disease (unresectable stage III and IV)

  • Surgical removal or stereotactic irradiation of locoregional recurrence or single distant metastasis.
  • First- and second-line treatments include anti-PD1 antibodies, PD-1 and ipilimumab, and BRAFi/MEKi combination for BRAF-mutated melanoma.
  • For brain metastases, ipilimumab/nivolumab is preferred first-line treatment.
  • For patients failing systemic treatment with 3 cm, stereotactic radiosurgery could be considered as salvage therapy if >5-10 progressing lesions with a maximal size >3 cm are present.